H.C. Wainwright Boosts ProMIS Neurosciences With 'Buy' Rating

ProMIS Neurosciences shares are trading higher after H.C. Wainwright initiated coverage with a 'Buy' rating and set a price target of $4.00, highlighting its novel therapeutic approaches in neurology.